Biocartis

Point-of-care molecular diagnostics instrumentation

Biocartis is a commercial stage company which develops novel molecular diagnostics. The proprietary Idylla™ platform is a fully automated, real-time system which provides accurate, highly-reliable RNA and protein expression information from any biological sample, thus improving diagnosis and facilitating personalised therapy at the point of care.

CEO  Rudi Pauwels

Advent Contact  Raj Parekh

Advent invested in the Series A in 2009. Biocartis listed on Euronext Brussels in 2015 (EBR:BCART).
Exited Investments
24 April 2015 in Biocartis, Press Release

Biocartis raises eur 100 million in successful initial public offering

Press Release.   Mechelen, Belgium, 24 April 2015 – Biocartis Group NV (the “Company” or “Biocartis”), an innovative molecular diagnostics company, today announces the results of its initial public offering,…
Read More
4 September 2014 in Biocartis, Press Release

Biocartis raises eur 64.5 million (approx. USD 85 million)

Press Release.   Investment supports commercial roll-out of Idylla™, Biocartis’ flagship molecular diagnostics system, and the development of the system’s menu of diagnostics tests.   Mechelen (Belgium), September 4, 2014…
Read More
12 December 2012 in Biocartis, Press Release

Biocartis completes €34,5million ($44,5 million) Series D Fund Raising

Press Release.   Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms. Strong support from internal shareholders and…
Read More
5 December 2012 in Biocartis, Press Release

Biocartis announces commercial launch of a new biomarker analysis platform

Press Release.   Lausanne, Switzerland – 5 December 2012 Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology (“DMAT”): New proteomic and nucleic acid platform provides ultra-high quality data analysis…
Read More
17 November 2011 in Biocartis, Press Release

Biocartis completes EUR 71 million (USD 100 million) Series C Fund Raising

Press Release.   Lausanne (Switzerland) – November 17, 2011. Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive the widespread adoption of personalized medicine and…
Read More
1 September 2011 in Biocartis, Press Release

Biocartis named as a Technology Pioneer 2012 by the World Economic Forum

Press Release.   Mechelen, Belgium. 1st September, 2011 – Biocartis today announces that it has been selected as a Technology Pioneer 2012 by the World Economic Forum. Technology Pioneers comprise…
Read More
12 April 2010 in Biocartis, Press Release

Biocartis raises €30 million in Series B’ financing round

Press Release.   Lausanne, Switzerland - Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on…
Read More
10 February 2010 in Biocartis, Press Release

Biocartis acquires Philips Technology Platform for Automated DNA/RNA Molecular Diagnostic Testing

Press Release.   Eindhoven, The Netherlands – Molecular diagnostics company Biocartis and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the signing of an agreement that will result in…
Read More
15 October 2009 in Biocartis, Press Release

Biocartis raises €10 million in Series A financing round

Press Release.   Lausanne, Switzerland, October 15th 2009 – Biocartis SA, a diagnostics company focused on fast and low-cost, integrated molecular and immunodiagnostics based on its proprietary micro-technology platform, today…
Read More